HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 745-756 of 4,505
Behavioral study icon
CompletedNCT04916626

The OPUS YOUNG study. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis

Official study title

The OPUS YOUNG Study. The Efficacy of Early Intervention Service Versus Treatment as Usual for Adolescents Aged 12 - 17 With First-episode Psychosis, a Pragmatic Randomized Clinical Trial

This study has finished and is no longer accepting participants.

In Hellerup
Schizophrenia, DepressionBehavioural studyAges 12–17
Countries
Denmark
Sponsor
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Drug study icon
WithdrawnNCT07084831

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in adults with Schizophrenia

What is this study about?

Researchers are studying Xanomeline/trospium to find out how it affects memory, attention and other thinking skills in adults with schizophrenia.

This study was withdrawn before enrollment.

Multiple locations, including Innsbruck
SchizophreniaMedication studyAges 18–55
Countries
Belgium, Austria, Czechia, + 7 others
Sponsor
European Group for Research In Schizophrenia
Drug study icon
CompletedNCT04659161

KarXT for schizophrenia

Official study title

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
CompletedNCT04738123

KarXT for schizophrenia

Official study title

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Bentonville
SchizophreniaMedication studyAges 18–65
Countries
United States, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
CompletedNCT07116850

Adjunctive iTBS for First-Episode Schizophrenia

Official study title

Adjunctive Intermittent Theta-Burst Stimulation for First-Episode Schizophrenia: A Randomized Clinical Trial

This study has finished and is no longer accepting participants.

In Shijiazhuang
SchizophreniaMedication studyAges 18–45
Countries
China
Sponsor
The First Hospital of Hebei Medical University
Drug study icon
CompletedNCT05414058

Adjunctive Methylphenidate ER in people with Schizophrenia to Improve Functional and Cognitive Outcomes

Official study title

Adjunctive Methylphenidate Extended Release in Patients With Schizophrenia: a Single-centre Fixed Dose Cross-over Open-label Trial to Improve Functional and Cognitive Outcomes

This study has finished and is no longer accepting participants.

In Ottawa
SchizophreniaMedication studyAges 18–55
Countries
Canada
Sponsor
The Royal Ottawa Mental Health Centre
Behavioral study icon
CompletedNCT04046497

Artificial Intelligence to Measure Adherence to Oral Medication

Official study title

Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication

This study has finished and is no longer accepting participants.

Multiple locations, including Hialeah
SchizophreniaInterventional studyAges 15–40
Countries
United States
Sponsor
Northwell Health

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.